2(S)-[2(S)-(4-guanidinomethyl-benzoylamino)-3-methyl-butyrylamino]-3-phenyl-propionic acid | 936571-73-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2(S)-[2(S)-(4-guanidinomethyl-benzoylamino)-3-methyl-butyrylamino]-3-phenyl-propionic acid
• CAS: 936571-73-2
• 化学式: C₂₃H₂₉N₅O₄
• 分子量: 439.514
• InChiKey: JREZNCXQGVWPBU-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.24
• 重原子数：
  32.0
• 可旋转键数：
  10.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  157.4
• 氢给体数：
  6.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2(S)-[2(S)-(4-guanidinomethyl-benzoylamino)-3-methyl-butyrylamino]-3-phenyl-propionic acid 、 苄胺 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.02h， 以45%的产率得到N-[1(S)-(1(S)-benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-methyl-propyl]-4-guanidinomethyl-benzamide
  参考文献：
  名称：

  Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

  摘要：

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.004
• 作为产物：
  描述：

  4-氨甲基苯甲酸 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.25h， 生成 2(S)-[2(S)-(4-guanidinomethyl-benzoylamino)-3-methyl-butyrylamino]-3-phenyl-propionic acid
  参考文献：
  名称：

  Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

  摘要：

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.004